

Hideto Tamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8034470/publications.pdf>

Version: 2024-02-01

66
papers

6,080
citations

471509

17
h-index

214800

47
g-index

71
all docs

71
docs citations

71
times ranked

9824
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 279.	3.7	8
2	Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1283-1294.	4.1	1
3	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2142-2150.	2.2	9
4	Clinicopathologic characteristics and <i>A20</i> mutation in primary thyroid lymphoma. <i>Journal of Nippon Medical School</i> , 2021, , .	0.9	1
5	CD155 and CD112 as possible therapeutic targets of <i>FLT3</i> inhibitors for acute myeloid leukemia. <i>Oncology Letters</i> , 2021, 23, 51.	1.8	9
6	A combination of check-point blockade and β -galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo. <i>Immunobiology</i> , 2020, 225, 151860.	1.9	5
7	The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma. <i>Experimental Hematology</i> , 2020, 90, 72-79.	0.4	5
8	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. <i>Molecular Cancer Research</i> , 2020, 18, 632-643.	3.4	12
9	PD-L1 in PD-1 Pathway in the Pathophysiology of Multiple Myeloma. <i>Cancers</i> , 2020, 12, 924.	3.7	41
10	Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 249, 19-28.	1.2	2
11	Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2019, 11, 2009.	3.7	20
12	Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. <i>Blood</i> , 2019, 134, 4361-4361.	1.4	1
13	Immunopathogenesis and immunotherapy of multiple myeloma. <i>International Journal of Hematology</i> , 2018, 107, 278-285.	1.6	53
14	Elotuzumab-induced interstitial lung disease: the first case report. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 491-494.	1.3	6
15	Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab. <i>Blood</i> , 2018, 132, 4439-4439.	1.4	1
16	Clinical impact of serum soluble SLAMF7 in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34784-34793.	1.8	27
17	A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma. <i>Blood</i> , 2018, 132, 5320-5320.	1.4	0
18	Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report. <i>Allergology International</i> , 2017, 66, 497-498.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Retrospective analysis of prognostic factors for Waldenström macroglobulinemia: a multicenter cooperative study in Japan. <i>International Journal of Hematology</i> , 2017, 106, 681-690.	1.6	3
20	Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 88904-88917.	1.8	52
21	Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. <i>JCI Insight</i> , 2016, 1, e85061.	5.0	32
22	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents era. <i>Annals of Hematology</i> , 2016, 95, 1465-1472.	1.8	11
23	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. <i>Cancer Immunology Research</i> , 2016, 4, 779-788.	3.4	80
24	Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. <i>Leukemia and Lymphoma</i> , 2016, 57, 2204-2207.	1.3	9
25	Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. <i>Cancer Biomarkers</i> , 2016, 17, 21-32.	1.7	10
26	Retrospective Analysis of Prognostic Factors for Waldenström Macroglobulinemia: A Multicenter Cooperative Study in Japan. <i>Blood</i> , 2015, 126, 5028-5028.	1.4	0
27	Clinical Significance and Pathophysiological Function of the Tim-3/Galectin-9 Pathway in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 4117-4117.	1.4	0
28	Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine. <i>Blood</i> , 2014, 124, 4411-4411.	1.4	2
29	Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy. <i>Blood</i> , 2014, 124, 2018-2018.	1.4	0
30	Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2063-2063.	1.4	0
31	Effect of G-CSF on induction of ENA-78 and IL-8 in the patients with malignant lymphoma. <i>Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of Experimental Hematology / Chinese Association of Pathophysiology</i> , 2014, 22, 344-8.	0.2	0
32	YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells. <i>Blood</i> , 2013, 122, 1667-1667.	1.4	0
33	Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma. <i>Blood</i> , 2013, 122, 4320-4320.	1.4	0
34	CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients. <i>Blood</i> , 2013, 122, 2799-2799.	1.4	3
35	Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study. <i>Leukemia Research</i> , 2012, 36, 1229-1236.	0.8	16
36	Disease progression mechanism in myelodysplastic syndromes: Insight into the role of the microenvironment. <i>Leukemia Research</i> , 2011, 35, 1449-1452.	0.8	19

#	ARTICLE	IF	CITATIONS
37	B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior. <i>Blood</i> , 2011, 118, 474-474.	1.4	0
38	Interferon- β and tumor necrosis factor- α induce an immunoinhibitory molecule, B7-H1, via nuclear factor- κ B activation in blasts in myelodysplastic syndromes. <i>Blood</i> , 2010, 116, 1124-1131.	1.4	179
39	Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 986-990.	0.8	24
40	Expression and Function of B7 Family Molecules in Hematologic Malignancies. <i>Journal of Nippon Medical School</i> , 2010, 77, 45-47.	0.9	0
41	Clinical Features of AL Amyloidosis Diagnosed via Renal Biopsy, and Response to Treatment. <i>Journal of Nippon Medical School</i> , 2010, 77, 348-351.	0.9	0
42	Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage. <i>Clinical Cancer Research</i> , 2009, 15, 770-777.	7.0	28
43	Interferon- β and Tumor Necrosis Factor- α Induce An Immunoinhibitory Molecule, B7-H1, Via Nf κ B Activation in Blasts of Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 2766-2766.	1.4	0
44	Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 3821-3821.	1.4	0
45	Chronic Active Epstein-Barr Virus Infection Complicated with Acute Myeloid Leukemia, Squamous Cell Carcinoma and Diffuse Panbronchiolitis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2008, 97, 1081-1082.	0.0	0
46	Expression and Function of B7.2 and B7-H2 Molecules on Myeloma Cells. <i>Blood</i> , 2008, 112, 2722-2722.	1.4	4
47	Expression of WT-1 mRNA in Peripheral Blood from Myelodysplastic Syndromes. <i>Blood</i> , 2008, 112, 3637-3637.	1.4	0
48	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes: A Prospective Validation Study in Low-Risk Patients with Normal Karyotype. <i>Blood</i> , 2008, 112, 3634-3634.	1.4	1
49	Increased apoptosis of circulating T cells in myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, 1641-1648.	0.8	16
50	Pure White Cell Aplasia: Report of the First Case Associated with Primary Biliary Cirrhosis. <i>International Journal of Hematology</i> , 2007, 85, 97-100.	1.6	8
51	Expression and Function of B7 Family Molecules on Blasts of Patients with Myelodysplastic Syndromes. <i>Journal of Nippon Medical School</i> , 2007, 74, 85-86.	0.9	1
52	B7.2 and B7-H2 Molecules Stimulate Proliferation of Myeloma Cells and Inhibit Anti-Myeloma Immune Responses.. <i>Blood</i> , 2007, 110, 3524-3524.	1.4	0
53	Expression of Functional B7-H1 Molecules on Blasts from Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 2429-2429.	1.4	0
54	Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 5708-5717.	7.0	111

#	ARTICLE	IF	CITATIONS
55	Flow Cytometric Characteristics of CD34+ Cells in Refractory Anemia: Their Diagnostic Value.. Blood, 2005, 106, 4896-4896.	1.4	0
56	Identification and Hematopoietic Potential of CD45-Negative Clonal Cells with Very Immature Phenotype (CD45 ⁺ CD34 ⁺ CD38 ⁺ Lin ⁻) in Patients with Myelodysplastic Syndromes.. Blood, 2004, 104, 3426-3426.	1.4	0
57	Immunology of B7-H1 and Its Roles in Human Diseases. International Journal of Hematology, 2003, 78, 321-328.	1.6	34
58	B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity. Immunity, 2003, 18, 849-861.	14.3	623
59	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. Journal of Clinical Investigation, 2003, 111, 363-370.	8.2	164
60	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 2002, 8, 793-800.	30.7	4,217
61	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood, 2001, 97, 1809-1816.	1.4	201
62	Repeated Cycles of G-CSF-Combined Postremission Chemotherapy for Acute Myeloid Leukemia in a First Complete Remission: A Pilot Study. Stem Cells, 1998, 16, 280-287.	3.2	2
63	FAILURE TO DETECT ANTI-HTLV-1 ANTIBODY IN A PATIENT WITH ADULT T-CELL LEUKAEMIA/LYMPHOMA. British Journal of Haematology, 1998, 103, 1207-1208.	2.5	1
64	Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia. , 1997, 55, 166-167.		6
65	Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. British Journal of Haematology, 1996, 93, 45-52.	2.5	12
66	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1